Regarding the rate of actionable mutations in lung cancer, we found that using NGS could contribute to optimize the detection of these mutations, observing a prevalence of actionable mutations with a specific targeted therapy available of 12.0%, being KRAS p.Gly12Cys the most frequent actionable mutation. This evidence concerns the gene KRAS and lung cancer.